256 related articles for article (PubMed ID: 9369342)
1. 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine.
Assié MB; Cosi C; Koek W
Eur J Pharmacol; 1997 Sep; 334(2-3):141-7. PubMed ID: 9369342
[TBL] [Abstract][Full Text] [Related]
2. The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.
Prinssen EP; Kleven MS; Koek W
Eur J Pharmacol; 1998 Sep; 356(2-3):189-92. PubMed ID: 9774248
[TBL] [Abstract][Full Text] [Related]
3. The role of 5-HT1A autoreceptors and alpha1-adrenoceptors in the modulation of 5-HT release--III. Clozapine and the novel putative antipsychotic S 16924.
Bengtsson HJ; Kullberg A; Millan MJ; Hjorth S
Neuropharmacology; 1998; 37(3):349-56. PubMed ID: 9681933
[TBL] [Abstract][Full Text] [Related]
4. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens.
Ichikawa J; Meltzer HY
Brain Res; 2000 Mar; 858(2):252-63. PubMed ID: 10708676
[TBL] [Abstract][Full Text] [Related]
5. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
Dekeyne A; Rivet JM; Gobert A; Millan MJ
Neuropharmacology; 2001 Jun; 40(7):899-910. PubMed ID: 11378160
[TBL] [Abstract][Full Text] [Related]
6. Effects of WAY 100635 and (-)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist, on 8-OH-DPAT responses.
Trillat AC; Malagié I; Mathé-Allainmat M; Anmela MC; Jacquot C; Langlois M; Gardier AM
Eur J Pharmacol; 1998 Apr; 347(1):41-9. PubMed ID: 9650846
[TBL] [Abstract][Full Text] [Related]
7. Activity of serotonin (5-HT) receptor agonists, partial agonists and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells.
Pauwels PJ; Van Gompel P; Leysen JE
Biochem Pharmacol; 1993 Jan; 45(2):375-83. PubMed ID: 8382063
[TBL] [Abstract][Full Text] [Related]
8. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties.
Assié MB; Koek W
Eur J Pharmacol; 1996 May; 304(1-3):15-21. PubMed ID: 8813579
[TBL] [Abstract][Full Text] [Related]
9. Estimation of apparent pA2 values for WAY 100635 at 5-HT1A receptors regulating 5-hydroxytryptamine release in anaesthetised rats.
Assié MB; Koek W
Eur J Pharmacol; 2000 Dec; 409(2):173-7. PubMed ID: 11104831
[TBL] [Abstract][Full Text] [Related]
10. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential.
Koek W; Patoiseau JF; Assié MB; Cosi C; Kleven MS; Dupont-Passelaigue E; Carilla-Durand E; Palmier C; Valentin JP; John G; Pauwels PJ; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1998 Oct; 287(1):266-83. PubMed ID: 9765347
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors.
Tordera RM; Monge A; Del Río J; Lasheras B
Eur J Pharmacol; 2002 May; 442(1-2):63-71. PubMed ID: 12020683
[TBL] [Abstract][Full Text] [Related]
12. Imipramine but not 5-HT(1A) receptor agonists or neuroleptics induces adaptive changes in hippocampal 5-HT(1A) and 5-HT(4) receptors.
Zahorodna A; Tokarski K; Bijak M
Eur J Pharmacol; 2002 May; 443(1-3):51-7. PubMed ID: 12044792
[TBL] [Abstract][Full Text] [Related]
13. Biochemical, electrophysiological and neurohormonal studies with B-20991, a selective 5-HT1A receptor agonist.
Caicoya AG; Beneytez ME; Delgado M; Manzanares J; López-Rodríguez ML; Benhamu B; Morcillo MJ; Pozo MA; Rubia FJ; Fuentes JA
Pharmacology; 2001 May; 62(4):234-42. PubMed ID: 11360001
[TBL] [Abstract][Full Text] [Related]
14. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
15. Role of 5-HT1A receptors in the ability of mixed 5-HT1A receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats.
Kleven M; Prinssen EP; Koek W
Eur J Pharmacol; 1996 Oct; 313(1-2):25-34. PubMed ID: 8905325
[TBL] [Abstract][Full Text] [Related]
16. Two selective 5-HT1A receptor antagonists, WAY-100 635 and NDL-249, stimulate locomotion in rats acclimatised to their environment and alter their behaviour: a behavioural analysis.
Jackson DM; Wallsten CE; Jerning E; Hu PS; Deveney AM
Psychopharmacology (Berl); 1998 Oct; 139(4):300-10. PubMed ID: 9809851
[TBL] [Abstract][Full Text] [Related]
17. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.
Ichikawa J; Ishii H; Bonaccorso S; Fowler WL; O'Laughlin IA; Meltzer HY
J Neurochem; 2001 Mar; 76(5):1521-31. PubMed ID: 11238736
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture.
Dumuis A; Sebben M; Bockaert J
Mol Pharmacol; 1988 Feb; 33(2):178-86. PubMed ID: 2828913
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ
Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
De Vry J; Schohe-Loop R; Heine HG; Greuel JM; Mauler F; Schmidt B; Sommermeyer H; Glaser T
J Pharmacol Exp Ther; 1998 Mar; 284(3):1082-94. PubMed ID: 9495870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
